Protocols

Based on available clinical trial evidence, low-dose naltrexone (LDN) protocols vary depending on the condition being treated, though specific dosing details from the referenced studies are limited in the provided abstracts.

General Dosing Approach

The literature suggests that LDN typically involves much lower doses than those used for opioid addiction treatment. The term "low-dose" generally refers to dosing significantly below the standard naltrexone dose of 50mg daily used for substance abuse disorders.

Clinical Trial Protocols

Several completed Phase 2 trials have investigated LDN protocols:

Fibromyalgia: The INNOVA Study was a 12-month randomized, double-blind, placebo-controlled trial specifically examining LDN efficacy in women with fibromyalgia syndrome, though specific dosing protocols are not detailed in the available abstract.
Pediatric Crohn's Disease: A completed Phase 2 trial investigated LDN efficacy in children with Crohn's disease, indicating protocols have been developed for pediatric populations.
COVID-19: LDN was studied in combination with colchicine for COVID-19 treatment in a completed Phase 2 trial.
Vulvodynia: An ongoing Phase 2 trial is examining LDN effectiveness for different types of vulvodynia.

Administration Considerations

The available evidence suggests LDN protocols involve oral administration, as indicated by the veterinary case series mentioning "oral low-dose naltrexone." However, specific details regarding timing of administration, titration schedules, or duration of treatment are not provided in the available abstracts.

Evidence Limitations

The current evidence base provides limited specific protocol details. While multiple clinical trials have been completed or are ongoing, the available abstracts do not contain detailed dosing regimens, titration schedules, or specific administration guidelines.

Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. LDN protocols should only be determined and supervised by qualified healthcare providers familiar with the patient's specific condition and medical history.

Low-Dose Naltrexone (LDN)

Member access required